QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Grossman, S. A. Articles by Holmlund, J. T. Search for Related Content PubMed PubMed Citation

Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C- delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas

The New Approaches to Brain Tumor Therapy CNS Consortium, Baltimore, MD 21231 (S.A.G., J.B.A., J.G.S., K.A.C., R.P.); Isis Pharmaceuticals, Inc., Carlsbad, CA 92008 (F.A.D., J.S.G., J.T.H.)

³ Address correspondence to Stuart A. Grossman, The New Approaches to Brain Tumor Therapy CNS Consortium, 1650 Orleans Street, Room G93, Baltimore, MD 21231 (grossman{at}jhmi.edu).

Abstract

Protein kinase C alpha (PKC-) is a cytoplasmic serine threonine kinase involved in regulating cell differentiation and proliferation. Aprinocarsen is an antisense oligonucleotide against PKC- that reduces PKC- in human cell lines and inhibits a human glioblastoma tumor cell line in athymic mice. In this phase 2 study, aprinocarsen was administered to patients with recurrent high-grade gliomas by continuous intravenous infusion (2.0 mg/kg/day for 21 days per month). Twenty-one patients entered this trial. Their median age was 46 years (range, 28-68 years), median Karnofsky performance status was 80 (range, 60-100), median tumor volume was 58 cm³ (range, 16-254 cm³), and histology included glioblastoma multiforme (n = 16), anaplastic oligodendroglioma (n = 4), and anaplastic astrocytoma (n = 1). The number of prior chemotherapy regimens included none (n = 3), one (n = 10), and two (n = 8). No tumor responses were observed. Patients on this therapy rapidly developed symptoms of increased intracranial pressure with increased edema, enhancement, and mass effect on neuroimaging. The median time to progression was 36 days, and median survival was 3.4 months. The observed toxicities were mild, reversible, and uncommon (grade 3 thrombocytopenia [n = 3] and grade 4 AST [n = 1]), and no coagulopathy or CNS bleed-ing resulted from this therapy. Plasma concentrations of aprinocarsen during the infusion exhibited significant interpatient variability (mean = 1.06 µg/ml; range, 0.34-6.08 µg/ml). This is the first study to use an antisense oligonucleotide or a specific PKC- inhibitor in patients with high-grade gliomas. No clinical benefit was seen. The rapid deterioration seen in these patients could result from tumor growth or an effect of aprinocarsen on blood-brain barrier integrity.

This article has been cited by other articles:

				S. S. Palaniyandi, L. Sun, J. C. B. Ferreira, and D. Mochly-Rosen Protein kinase C in heart failure: a therapeutic target? Cardiovasc Res, May 1, 2009; 82(2): 229 - 239. [Abstract] [Full Text] [PDF]

				S. Phuphanich, K. A. Carson, S. A. Grossman, G. Lesser, J. Olson, T. Mikkelsen, S. Desideri, J. D. Fisher, and for the New Approaches to Brain Tumor Therapy (NAB Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma Neuro-oncol, August 1, 2008; 10(4): 617 - 623. [Abstract] [Full Text] [PDF]

				K. A. Carson, S. A. Grossman, J. D. Fisher, and E. G. Shaw Prognostic Factors for Survival in Adult Patients With Recurrent Glioma Enrolled Onto the New Approaches to Brain Tumor Therapy CNS Consortium Phase I and II Clinical Trials J. Clin. Oncol., June 20, 2007; 25(18): 2601 - 2606. [Abstract] [Full Text] [PDF]